Advances in the DNA hybrid technology led to the development of various biologicals that specifi cally target TNF-α. There are currently three anti-TNF-α drugs available-etanercept, infl iximab and adalimumab.
Tumour Necrosis Factor (TNF)-α, a potent cytokine is a soluble 17-Kd protein with three identical subunits. TNF is produced by the body and is involved in normal inflammatory and immune responses. [1] It is both autocrine and paracrine inducer of other cytokines like IL(interleukin)-1, IL-6, IL-8, platelet derived growth factor-B, ecosanoids, platelet activating factors and granulocyte monocyte colony stimulating factor. Anti TNF-α therapy down-regulates the monocyte capacity to produce proinfl ammatory cytokines and induces a shift to produce more anti-infl ammatory TH2 cytokine. Anti-infl ammatory cytokines are IL-4, IL-10, IL-11, IL-13, IL-16, transforming growth factor ß, soluble TNF-receptor and soluble interleukin-1 receptor. [2] With the development of biologicals against TNF-α, our therapeutic approach to infl ammatory diseases has dramatically changed. Advances in the DNA hybrid technology led to the development of various biologicals that specifi cally target TNF-α. There are currently three anti-TNF-α drugs available: -etanercept, infl iximab and adalimumab [ Table 1 ]. Etanercept is a recombinant fusion protein that consists of two soluble TNF-α p75 receptor moieties linked to the Fc portion of human IgG. [1] It was approved by FDA for rheumatoid arthritis (RA) in 2000, followed by its approval for ankylosing spondylitis, psoriasis and psoriatic arthritis. [3] Infl iximab [chimeric (25%mouse and 75%human)] and adalimumab [human-derived antibody] are the monoclonal antibodies against TNF-α and are approved by FDA in 2002 for RA. [2] Infliximab is also approved for ankylosing spondylitis, psoriasis, psoriatic arthritis, crohn's disease and ulcerative colitis; whereas; adalimumab is approved for psoriatic arthritis and ankylosing spondylitis. [3, 4] In the present article we are going to summarize various therapeutic indications for novel anti-TNF therapies [ Table 2 and 3].
Search Methodology
Prominent rheumatology and general/internal medicine journals (MEDLINE, EMBASE, PUBMED between 2000 [2] ASPIRE phaseIII RCT RA Infl iximab+ MTX MTX Combination produced better effect. [2] Double blind RCT RA Etanercept +MTX Either drug alone Combination produced better effect. [2] BeSt Trial (Questionnaire) RA MTX + Infl iximab DMRDs MTX + Infl iximab better than other DMRDs. [2] Double blind RCT AS Etanercept Placebo >Etanercept patients showed ASAS 50 responses. [9] 3 month RCT AS Infl iximab Placebo Infl iximab more effective than placebo. [9] Anti-TNF RCT AS Etanercept Placebo At 24 weeks, etanercept more effective than placebo. [11] Infl iximab safety database Pregnancy Infl iximab exposed Non exposed Pregnancy outcome same. [17] with CD (131) Double blind RCT PsA Infl iximab Cyclosporine Infl iximab has effi cacy and rapidity of onset of therapeutic effect similar to cyclosporine. [6, 22] Double blind RCT PsA Etanercept Placebo Improvement in the PASI was signifi cantly more in etanercept group then placebo. [23] Phase III, double blind trial PsA Infl iximab Placebo Infl iximab through 24 weeks signifi cantly improved active PsA, including dactylitis and enthesopathy and associated psoriasis. [24] Multicenter, double-blind, RCT PsA with failure Infl iximab Placebo ACR20 response at week 16, was higher in of at least infl iximab group. [25] 1 DMRD Pilot study AD Infl iximab -Induction therapy with infl iximab signifi cantly improved all clinical parameters. [27] Pilot study RU Infl iximab -Infl iximab was found to be effective both as shortterm (10 weeks) and long term therapy (50 weeks). [30] ATLAS trial AS Adalimumab Placebo Adalimumab is more effective in reducing disease activity. [4] Phase II, RCT SPS CytoFab Human albumin CytoFab promptly reduced plasma TNF-α and IL-6 as placebo concentrations compared with placebo. CytoFab increased mean ventilator-free days and ICU-free days at day 28. [39] Clinical trial AS Infl iximab 15 Clinically signifi cant improvement was found in all patients without any incidence of TB after 52 weeks. [40] Clinical trial AS, polyarticular JIA, Infl iximab 176 Reactivated TB developed in 10.6% SpA patients treated with RA, undifferentiated standard doses (5 mg/kg) of infl iximab. [41] Infl iximab showed SpA, IBD-related expected effi cacy in SpA, RA and JIA spondyloarthritis and PsA Open label PsA Infl iximab 3 All patients attained PASI 50 by 3.8 weeks. PASI 75 was pilot study attained at 9.6 weeks. Relapse occurred at a mean of 18.6 weeks after the fi rst infusion. [42] RA -Rheumatoid arthritis, AS -Ankylosing spondylitis, PsA -Psoriatic arthritis, SpA -Spondyloarthropathy, IBD -Infl ammatory bowel disease, JIA -Juvenile idiopathic arthritis, PASI -Psoriasis area and severity index, ACR -American College of Rheumatology preliminary criteria for improvement and 2006) were searched for review papers and clinical trials published on therapeutic uses of anti-TNF therapy. All the data was collected and important evidences regarding use of anti-TNF agents were summarized in the present article.
Therapeutic Indications of Anti-TNF Drugs
Rheumatoid arthritis (RA) [ 
2,5]
The TNF plays an important role in both pathological infl ammation and joint destruction that are hallmark of RA. Anti-TNF therapy has revolutionized the approach in management of RA. In phase-III RCTs (randomized control trials) like ASPIRE and ATTRACT infl iximab (3 mg/kg or 10 mg/kg) regimen was found to be superior to MTX (methotraxate) alone. In a double blind RCT, on 686 patients with active RA the combination of etanercept 25 mg (subcutaneously twice a week) and oral MTX (up to 20 mg every week) was signifi cantly better in reducing disease activity, improving functional disability and retarding radiographic progression than MTX or etanercept alone.
In a 52-week double blind clinical trial, patients with active RA were randomized to receive etanercept 25 mg twice weekly or MTX up to 20 mg weekly or combination therapy. Combination therapy with etanercept and MTX improved function, quality of life and satisfaction with medication signifi cantly better than mono-therapy. In BeSt trial (where questionnaire was fi lled by each patient to give the responses in relation to different anti-rheumatic drug regimens), MTX and infl iximab combination found to be benefi ting greatly then other DMRDs (disease modifying drugs). In a study on total of 2662 patients (infl iximab = 141; etanercept = 853; and MTX = 1668), compliance with at least 80% of the expected dosages was signifi cantly lower for etanercept and MTX patients than infl iximab patients. Currently, anti-TNF therapy is recommended for patients, who fail to respond or tolerate at least 2 DMRDs including MTX.
Ankylosing spondylitis (AS)
AS affects about 0.5%-1.0% of the population and typically begins between the ages of 15 and 40 years. [5] It causes painful stiffness of the spine, progressive disability and loss of independence during the prime productive years. Anti-TNF-α agents have been found to be very effective for the treatment of both peripheral and axial symptoms in patients with AS. [6, 7] In a double blind RCT, out of 84 patients of AS, 45 received etanercept and 39 received placebo. [8] Signifi cantly more etanercept patients reported ASAS (the multicomponent Assessments in AS) 50 responses at all times and ASAS 70 responses at weeks two, four and eight. Patients in the etanercept group reported lower composite and fatigue BASDAI (Bath AS Disease Activity Index) scores, lower acute phase reactant levels and improvement in spinal fl exion. [8] In a three-month clinical trial, 18 of 34 patients (53%) treated with infl iximab met the predefi ned response criterion, compared with three of 35 (9%) patients receiving placebo. [9] These improvements persisted during the open-label extension study in which all participants were given infl iximab for an additional 42 weeks. [10] In another RCT, 277 patients with AS received either etanercept or placebo. [11] At 24 weeks, 59% of patients in the etanercept group and 28% patients of the placebo group met the ASAS-20 criteria for response. Data from Phase III adalimumab trial evaluating long-term effi cacy and safety in AS (ATLAS trial) on 315 patients demonstrated ASAS-20 response in 58% patients receiving adalimumab at 12 weeks. [4] At week 24, 42% of adalimumab-treated patients and 16% of those receiving placebo achieved a reduction of 50% or more in disease activity. [4] Recent trials have shown that anti-TNF therapy is more effective in AS than in RA. [12] However, patient's benefi ts from long-term treatment, effects on radiological progression and long-term safety of biologic therapy are still needed to be explored.
Crohn's disease and ulcerative collitis
Stenoses and fi stulas are frequent complications in patients with Crohn's disease (CD). Infl iximab is effective in the treatment of patients with moderately to severely active Crohn's disease with an inadequate response to other treatment options or those with fi stulizing disease. [13] [14] [15] It is administered intravenously, generally in a schedule with initial infusions at 0, 2 and 6 weeks, followed by administration once every eight weeks. [13, 14] Clinical evidence suggested that a single intravenous infusion of infl iximab may be effective for induction of remission in Crohn's disease. [16] The results of two trials suggested that CDP571, the genetically engineered human TNF monoclonal antibody, is also effective in reducing disease activity index at two weeks after an infusion. [16] Clinical experience suggests that infl iximab is also be effective when administered as corticosteroid-sparing therapy. [15] Data from the infl iximab safety database suggest that infliximab exposure during pregnancy (of the 146 identifi ed pregnancies, 131 involved women exposed directly to infl iximab and outcome data were available for 96 of these women) results in outcomes that are similar to those in the U.S. population of pregnant women and pregnant women with CD not exposed to infl iximab. [17] However, follow-up of larger numbers of pregnant women exposed to infl iximab will be necessary to defi nitively exclude any fetal risk.
In a RCT, 20 patients of steroid-dependent ulcerative colitis received either three infusion of infl iximab (5 mg/kg) at zero, two and six weeks and thereafter every eight weeks (group A) or methylprednisolone (0, 7-1 mg/kg) daily for one week followed by a tapering regimen up to the minimal dose to maintain a symptom-free condition (group B). [18] Infl iximab seems to be as effective as steroids in the management of the disease. In another RCT on patients with glucocorticoid resistant ulcerative colitis, no statistically signifi cant difference was seen between the infl iximab and placebo groups. [19] Hence, data do not support the use of infl iximab in the management of moderately active glucocorticoid resistant ulcerative colitis. However, recently in a RCT patients with severe to moderately severe ulcerative colitis not responding to conventional treatment, were randomized to receive infliximab (24) or placebo (21) . [20] Seven patients in the infl iximab group and 14 in the placebo group had a colectomy (P=0.017) within three months after randomization. Moreover, three patients in the placebo group required operation for septic complications. The study clearly indicated the role of Infl iximab 4-5 mg/kg in patients experiencing an acute severe or moderately severe attack of ulcerative colitis not responding to conventional treatment.
Psoriasis and psoriatic arthritis (PsA)
TNF-α inhibitors are among the new class of drugs that offer new options for psoriasis control. [21] TNF-α increases in the psoriatic skin lesion and in the synovium of the infl amed joint. [21] A double blind trail by Chaudhari et al., showed a > 75% improvement in psoriasis, area and severity index score at week 10 in 82% patients receiving infl iximab 5 mg/kg at weeks 0, 2 and 6. [22] Etanercept has also been shown to possess good effi cacy in moderate to severe psoriasis. In a double-blind RCT (12 week study) 60 patients with PsA and psoriasis received either etanercept (25 mg twice-weekly subcutaneous injections) or placebo. [23] 26 (87%) of etanercept-treated patients met the Psoriatic Arthritis Response Criteria, compared with seven (23%) of placebo-controlled patients. The ACR20 (American College of Rheumatology preliminary criteria for improvement) was achieved by 22(73%) of etanercept-treated patients compared with 4(13%) of placebo-treated patients. [23] Improvement in the psoriasis area and severity index (PASI) was signifi cantly more in etanercept group then placebo. In a phase III, double blind trial 200 patients with active PsA unresponsive to previous treatment were randomized to infusions of infl iximab 5 mg/kg or placebo at weeks 0, 2, 6, 14 and 22. At week 14, 58% of patients receiving infl iximab and 11% of those receiving placebo achieved an ACR20 response (P<0.001). [24] 64% patients receiving infl iximab had at least 75% improvement in PASI compared with 2% patients receiving placebo at week 14 (P<0.001). [24] These therapeutic effects were maintained till week 24. In a multicentre RCT, 104 patients with PsA (with prior failure of at least 1 DMARD therapy) received infusions of infl iximab (5 mg/kg) or placebo at weeks 0, 2, 6 and 14. [25] After week 16, all patients received infl iximab 5 mg/kg every eight weeks through week 50. 65% of infl iximabtreated patients and 10% of placebo-treated patients achieved an ACR20 response at week 16. Moreover, 46% and 29% of infl iximab-treated patients achieved ACR50 and ACR70 responses respectively; no placebotreated patient achieved these end points. Hence, clinical experience so far clearly indicated the role of anti-TNF drugs in the management of psoriasis and PsA refractory to other DMRDs. [26] There are encouraging uncontrolled data in humans with infl iximab for anti-neutrophil cytoplasm antibody (ANCA)-associated systemic vasculitis (AASV). TNF-α plays an important role in the pathogenesis of experimental autoimmune vasculitis and blockade of this cytokine is effective in treating established vasculitis. The therapeutic action of anti-TNF-α agents may be mediated by suppression of the enhanced leukocyte-endothelial interactions in this disorder. However, clinical trials are needed to establish their role in systemic vasculitis. [27] Chronic use of standard therapies for atopic dermatitis (AD) is associated with variable effi cacy and potential side effects. Targeted therapeutic approaches, such as the inhibition of TNF-α, may be a novel option. In a pilot study, nine patients with moderate or severe AD received infl iximab 5 mg/kg by intravenous infusion at weeks zero, two, six, 14, 22, 30 and 38 and patients were followed for 46 weeks. Induction therapy with infl iximab signifi cantly improved all clinical parameters, but this improvement was not sustained through maintenance therapy. Only two patients with severe AD achieved an excellent clinical response by 46 weeks. Hence, long term RCTs are required to further establish the role of infl iximab and other anti-TNF-α agents in atopic dermatitis refractory to standard therapies. [ 
Systemic vasculitis

Atopic dermatitis
Congestive heart failure (CHF)
22,28,29]
Elevated TNF-α levels have also been observed in patients with CHF and clinical trials have been performed to examine the effects of TNF-α inhibitors, such as etanercept and infl iximab, in such a population.
TNF-α exerts negative inotropic effect, recapitulates cellular and biochemical abnormalities, uncouples ß-adrenergic receptors from adenylate cyclase, activates metalloproteinases and provokes a hypertrophic growth response in cardiac myocytes. Hence, anti-TNF-therapy seems to hold promises in treatment of CHF. Two largescale trials of etanercept in more than 2000 patients with heart failure did not indicate any increased risk of mortality or morbidity. In a clinical trial, 150 patients with stable New York Heart Association class III or IV heart failure and left ventricular ejection fraction <or=35% were randomly assigned to receive placebo (n=49), infl iximab 5 mg/kg (n=50) or infl iximab 10 mg/kg (n=51) at zero, two and six weeks. It was found that neither dose of infl iximab improved clinical status at 14 weeks. However, the combined risk of death from any cause or hospitalization for heart failure through 28 weeks was increased in the patients randomized to 10 mg/kg infl iximab. Hence, recent evidences clearly indicated adverse effect of anti-TNF therapy in patients with CCF. [30] In a study, 23 patients of refractory uveitis received three infl iximab infusions at weeks zero, two and six. Clinical success was ascertained at week 10 and patients meeting initial criteria for success received an infusion at week 14 and every eight weeks thereafter (dose escalation permitted for breakthrough infl ammation). Infl iximab was found to be effective both as short-term (week 10) and long term therapy (50 weeks of therapy). However, further studies are required to establish the safety of anti-TNF therapy in refractory uveitis. [6, 31, 32] It has been seen that recruitment of neutrophils and eosinophils associated with allergic condition is mediated via TNF-α. TNF-α is released in allergic responses, from mast cells and macrophages via IgE dependent mechanisms. Anti-TNF-α therapy may be useful as a glucocorticoid sparing asthma therapy. Anti-TNF-α therapy may also be effective in the treatment of certain allergic conditions including Jarisch-Herxheimer reaction. Asthma is regarded as a Th2 type disorder, especially when associated with atopy. However, TNF production is increased in severe corticosteroid-dependent asthma. Etanercept treatment was associated with improvement in asthma symptoms, lung function and bronchial hyperresponsiveness. However, further long term RCTs are required to establish the status of anti-TNF therapy in refractory bronchial asthma and allergic conditions.
Refractory uveitis
Bronchial asthma and allergic conditions
Sepsis and shock
TNF-alpha is involved in virtually all features of septic shock and multiple organ failure. Anti-TNF-alpha strategies are thus appealing and have been effective at reducing infl ammation and morbidity. [33] Evidences from various RCTs targeting TNF during sepsis, showed a small but signifi cant benefi t with anti-TNF therapeutic strategies. Strategies using monoclonal antibodies are more effective than are strategies using TNF receptor proteins. [34] A study in 2634 septic patients using a murine anti-TNF antibody showed a 3.6% signifi cant benefi t in reducing mortality. [34] Afelimomab, the F(ab')2 fragment of a murine anti-TNF-alpha antibody has been found to be effi cacious and well tolerated in 7300 patients with septic shock. [33, 34] In a Phase II, RCT, 81 septic patients with either shock or two organ dysfunctions were randomized to receive CytoFab (polyclonal ovine anti-TNF fragment antigen binding (Fab) fragments), infused as a 250-units/kg loading dose, followed by nine doses of 50 units/kg every 12 hours or 5 mg/kg human albumin as placebo. [35] CytoFab promptly reduced plasma TNF-α (P = 0.001) and IL-6 concentrations (P= 0.002) compared with placebo. CytoFab also signifi cantly decreased TNF-α in bronchoalveolar lavage (BAL) fl uid (P <.001). The number of shock-free days did not differ between CytoFab and placebo. CytoFab increased mean ventilator-free days and ICU (intensive care unit)-free days at day 28. However, 41% of CytoFab-treated patients developed detectable plasma levels of human anti-sheep antibodies. [35] However, better characterization of patients and a more multimodal approach by concomitantly targeting other mediators involved in sepsis may be helpful in enlarging the clinical benefi t of anti-TNF therapy. [36] TNF-α related apoptosis is involved in ß cell damage in type I diabetes, resulting into insulin resistance, impaired insulin signaling and formation of atherosclerotic vascular lesions in diabetic patients. It has been documented that anti-TNF-α therapy may be benefi cial in reducing the complications of diabetes. In a study on 4 women (52-76 years) with type 2 diabetes in danger of vision loss due to severe macular edema on hypoglycemic therapy, two infusions of infl iximab (5 mg/kg) in 1-month intervals intravenously showed signifi cant regression in macular edema. Long term RCTs are needed to establish the role of infl iximab like drugs in preventing diabetic complications. [37] Increased TNF-α levels in the cerebral post-ischemic infl ammatory response lead to stimulation of adhesive molecules expression, neuronal necrosis and neurodegeneration through inhibition of a vital survival signal, 1GF-I. The cytokine TNF-is elevated in Alzheimer's disease, Parkinson's disease, stroke and amyotrophic lateral sclerosis. Its synthesis can be reduced via posttranscriptional mechanisms with novel analogues of the classic drug, thalidomide. Moreover, there is need to explore the role of anti-TNF agents in neuro-degenerative disorders.
Diabetes Mellitus
Neuro-degenerative conditions
Other Conditions [6, 38] Monoclonal antibodies against TNF-α also have a potential in the management of cachexia of cancer, skin tumors such as basal cell carcinoma, colorectal cancers and ovarian cancers. In a study on 6 patients of active adult onset Still's syndrome (AOSD), the disease improved remarkably in all patients with and after treatment with infl iximab. Conditions like behcet's disease, bullous dermatitis, neutrophilic dermatitis, toxic epidermal necrolysis, systemic vasculitis, pyoderma gangrenosum, pustular dermatitis, alcoholic hepatitis, cerebral malaria, hemolytic uremic syndrome, preeclampsia, allograft rejection, otitis media, snakebite, erythema nodosum, myelodysplastic syndromes, graft versus host disease, dermatomyositis and polymyositis are other potential targets for anti-TNF-α therapy.
Anti TNF-therapies and Indian patients
Misra R, et al. in a phase IIIb study involving forty patients of RA over 18 years of age (6 male: 34 females), demonstrated ACR 20% response in 25%, 57.5% and 70% of patients at four, eight and 16 weeks respectively after etanercept 25 mg subcutaneous injection twice weekly for 16 weeks (along with concomitant use of prednisolone, MTX, non-steroidal anti-infl ammatory drug, folic or folinic acid as prescribed earlier). [2] The mean scores of all aspects of Short Form-36 Health Survey assessment of patient physical and mental functioning improved signifi cantly from baseline. [2] Moreover, the data from this study have shown etanercept to be effi cacious and well tolerated drug in Indian patients with RA.
In another study from Kolkata during 2002-2005 on patients of RA, AS, PsA and juvenile rheumatic arthritis, ACR 20 responses were obtained in all patients of RA with infl iximab 3mg/kg dose at 0, 2 and 6 weeks; however, 13% of the total patients developed TB (tuberculosis). [39] However, an other study on 15 patients of AS treated with infl iximab (3 mg/kg at every eight weeks for 52 weeks) showed clinically signifi cant improvement in all patients without any incidence of TB. [40] Data on infl iximab from 176 patients (147 AS, nine polyarticular juvenile idiopathic arthritis, 12 RA, six undifferentiated spondyloarthropathy, one infl ammatory bowel disease-related spondyloarthritis and one PsA) showed development of reactivated TB in 5/47 (10.6%) SpA patients treated with standard doses (5 mg/kg) of infl iximab. [41] This amounted to 56 times increased risk compared to baseline (0.187%). None of the 129 patients treated with 3 mg/kg infusions at eight-weekly intervals with omission of the two-week and six-week doses of infl iximab developed reactivation tuberculosis. Infl iximab showed expected effi cacy in SpA, RA and JIA. The lone study on etanercept showed good effi cacy in 40 patients with RA. [41] In an open label pilot study among three patients having moderate to severe plaque psoriasis, infl iximab was administered in a dose of 5 mg/kg as an intravenous infusion over two hours, diluted into 500 ml of normal saline at zero, two and six weeks. [42] All patients attained PASI 50 by 3.8 weeks. PASI 75 was attained at 9.6 weeks. [42] The mean improvement in PASI at week 10 stood at 77.2%. Relapse occurred at a mean of 18.6 weeks after the fi rst infusion. The fi rst patient, who also Table 4 : British society for rheumatology guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis [5] Eligibility criteria for biologic therapy: *Fulfi ll 1987 criteria of American college of Rheumatology for diagnosis of RA. *Active RA (DAS28 score >5.1) at 2 points one month apart. *Failure to respond or tolerate at least 2 DMRDs (disease modifying drugs) including MTX (methotrexate). *When other DMRDs are contraindicated.
Exclusion criteria: Pregnant and lactating mothers, active infection, septic arthritis in last 12 months, sepsis of prosthetic joint within last 12 months or indefi nitely if joint remains in situ, New York Heart Association (NYHA) grade 3or 4 of congestive cardiac failure (CCF) and Demyelinating disease. *Caution in patients with low immune status.
Conditions for with-drawl of biologic therapy: *Drug related toxicity. *Failure to improve DAS28 score by 1.2 or to reduce it to a score of <3.2 after 3 months of therapy. However, if there is decrease in dose of DMRDs, continue drug for 6 months and assess. *Severe intercurrent infection and pregnancy (temporary with-drawl).
Choice of anti-TNF therapy: *Patient's preference, practical issues like drug administration and delivery. *Etanercept and adalimumab can be given in patients intolerant to MTX. *Infl iximab and etanercepts can be interchanged in case of failure to one of the therapy. DMRDs can be combined. Follow recommended dose. had PsA, reported partial improvement in spinal stiffness and pain at two weeks and peripheral joint stiffness at six weeks. These improvements did not diminish at 22 weeks, end of the surveillance period. [42] Safety concerns with anti-TNF therapy [2, [43] [44] [45] [46] Reactivation of latent TB with TNF blockers is a cause of concern. More cases of TB have been reported with infl iximab than with etanercept or adalimumab. This higher incidence of TB with infl iximab could be because of its ability to disrupt granulomas leading to reactivation of TB and to fi x the complement and lyse the cells presenting TNF-α. Moreover, infliximab has longer half-life (210h) and can produce continuous blockade of TNF-α in irreversible manner in contrast to etanercept. Another point differentiating infl iximab and etanercept is blockade of both TNF-α receptor p55 and p75 mediated events by infl iximab and only p75 blockade is blocked by etanercept.
However, considering the risk of serious infections with the use of anti-TNF therapy, FDA recommended a black box for TB on the product labeling of infl iximab. According to British Thoracic Society recommendations following guidelines should be observed: 1. If there is prior history of TB, chest X-ray and clinical examination positive, fi rst treat the patient with antituberculosis chemotherapy before starting anti-TNF therapy. 2. If anti-TNF therapy has to be initiated earlier, complete two months anti-tuberculosis treatment or ensure drug susceptibility of the organism before starting the anti-TNF therapy. 3. If there is evidence of past history of TB or abnormal chest X-ray with complete treatment carefully monitor with chest X-ray after every three months. 4. If history of inadequate anti-TB therapy or risk of TB is more than risk of chemoprophylaxis, a full course of chemoprophylaxis should be given before starting anti-TNF-α therapy. 5. Tuberculin test is considered reliable only if patient is not taking immunosuppressive drugs or stopped them (one month for steroids and three months for others).
However, in developing countries like India with prevalence rate of TB of about 44%, a negative Mantoux test does not rule out TB. It is recommended to consider prophylactic anti-TB therapy with Isoniazid 5 mg/kg in patients before starting anti-TNF-α therapy. As there is increasing trend towards multidrug resistant TB, hence prophylaxis with two or three antitubercular drugs should also be considered. SLE syndrome, demylinating diseases, neurodegenerative diseases, pancytopenia, cardiovascular diseases etc. are the other important adverse effects reported with anti-TNFα therapy. However, it has been recommended that anti-TNF drugs should not be used in pregnant and lactating mothers, active infection, septic arthritis in last 12 months, sepsis of prosthetic joint within last 12 months or indefi nitely if joint remains in situ, NYHA grade 3 or 4 of CCF and demyelinating disease [ Table 4 ].
Conclusion
Anti-TNF-α agents have been found very effective for the treatment of various immuno-infl ammatory conditions (table-5). Currently anti-TNF drugs are approved by FDA for use in RA, PsA, psoriasis, CD, ulcerative collitis and AS. Sepsis, bronchial asthma and allergic conditions are other diseases in pipeline for approval. However, their use is limited by cost and uncertainty over long-term effi cacy and safety. Etanercept, infl iximab and adalimumab can be given in patients intolerant or refractory to other DMRDs. [5] Infl iximab and etanercept can be interchanged in case of failure to one of the therapy. [5] Genetic variability in the production and effecter pathways of TNF-α determines the effect of anti-TNF therapy. Meta-analyses have suggested that etanercept shows modest superiority over infl iximab or adalimumab. [47] Reactivation of latent TB with TNF blockers is a cause of concern. More cases of TB have been reported with infl iximab than with etanercept or adalimumab. Etanercept [Rs 20800($451.20)/100 mg] and infl iximab [Rs16500($357.50)/25 mg] are two biologics available in India. [2] It is recommended to consider prophylactic anti-TB therapy before starting anti-TNF-α therapy, as India has 44% prevalence rate of TB. However, extensive post-marketing surveillance is necessary to re-evaluate the risk-benefi t ratio of these biologic therapies. Prescriber should evaluate all the available evidences before prescribing an anti-TNF-α agent for various potential indications. ) .
